Grants and Contributions

• The CIHR Institute of Indigenous Peoples’ Health (IIPH) will provide funding for applications that are relevant to it’s mandate .

The objective is to invest in targeted COVID priority research areas from the Fall 2020 Project Grant competition such as vaccine hesitancy, pregnant women and children, racialized populations, Indigenous, confidence in science and SARS-CoV-2 variants.

The objective is to invest in targeted COVID priority research areas from the Fall 2020 Project Grant competition such as vaccine hesitancy, pregnant women and children, racialized populations, Indigenous, confidence in science and SARS-CoV-2 variants.

The objective is to invest in targeted COVID priority research areas from the Fall 2020 Project Grant competition such as vaccine hesitancy, pregnant women and children, racialized populations, Indigenous, confidence in science and SARS-CoV-2 variants.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

• Funding will be provided for applications that specifically align with IHSPR’s mandate and one or more of the following priority areas:

o Virtual care1 approaches and their implications on access, continuity, experience, equity, cost and/or outcomes of care.
o Cross-jurisdictional healthcare policy/systems/services analysis that utilizes the Canadian Data Platform, with linkages to additional novel data sources (e.g., EMRs, hospital administrative data, patient-reported experience measures (PREMS) and patient-reported outcome measures (PROMS)).
o Models of care that optimize inter-professional collaboration and/or integration of services across sectors for the improvement of patient outcomes and timely access to high quality, appropriate care for all.
o Cross-jurisdictional comparative policy analysis of the COVID-19 response and outcomes (e.g., policies, processes and interventions implemented in response to the pandemic).
o System adaptation and organization of care and the healthcare workforce as it relates to the COVID-19 pandemic. Areas of focus include the primary, home and community care sectors (including long-term care).

• The CIHR Institute of Human Development, Child and Youth Health (CIHR-IHDCYH) will provide bridge funding for a applications that are relevant to its mandate:
o As a life-cycle based Institute, IHDCYH has a broad mandate that covers defined time periods and a wide range of issues pertaining to human development: pre-conception; fertilization; embryonic and fetal development; the health of the mother and father; and the health and development of infants, children and youth.

• Funding will be provided for applications that specifically align with IHSPR’s mandate and one or more of the following priority areas:

o Virtual care1 approaches and their implications on access, continuity, experience, equity, cost and/or outcomes of care.
o Cross-jurisdictional healthcare policy/systems/services analysis that utilizes the Canadian Data Platform, with linkages to additional novel data sources (e.g., EMRs, hospital administrative data, patient-reported experience measures (PREMS) and patient-reported outcome measures (PROMS)).
o Models of care that optimize inter-professional collaboration and/or integration of services across sectors for the improvement of patient outcomes and timely access to high quality, appropriate care for all.
o Cross-jurisdictional comparative policy analysis of the COVID-19 response and outcomes (e.g., policies, processes and interventions implemented in response to the pandemic).
o System adaptation and organization of care and the healthcare workforce as it relates to the COVID-19 pandemic. Areas of focus include the primary, home and community care sectors (including long-term care).

The specific objectives of this funding opportunity are:

• Identify wise programs, policies or actions, and/or address critical knowledge gaps, including data, related to further understanding of the immediate impacts and/or future consequences of COVID-19 among First Nations, Inuit, Métis and/or Urban Indigenous populations, communities and/or individuals;
• Identify, implement and evaluate culturally safe, and community-led solutions to address the COVID-19 pandemic and its immediate and/or future consequences among First Nations, Inuit, Métis and/or Urban Indigenous communities;
• Accelerate First Nations, Inuit, Métis and/or Urban Indigenous community-led knowledge translation and knowledge mobilization activities related to COVID-19 within the context of Indigenous health; and
• Inform and contribute to relevant research capacity and infrastructure, or adapt existing programs and infrastructure, in First Nations, Inuit, Métis and/or Urban Indigenous communities to enable Indigenous communities to design, lead, and meaningfully participate in culturally safe responses to the COVID-19 pandemic.

The overall goal of this pan-Canadian initiative is to position Canada for the rapid translation of epigenetic discoveries into diagnostic procedures and the eventual development of new therapeutics that can improve human health. By supporting and applying epigenetics research on a national scale, CEEHRC is harnessing its great potential for major breakthroughs in understanding the origins of health and also the etiology, treatment and prevention of many of the chronic diseases currently affecting the Canadian population. Specific CEEHRC objectives include:
•Establishment of a national epigenetics platform that will serve as an essential resource for the generation of human reference epigenomes and that will coordinate national efforts in epigenomic research.
•Translation of epigenetic research discoveries into clinical and medical practice by supporting large-scale epigenetics research. This includes the development of novel molecular tools for diagnostic and therapeutic applications to a wide range of complex disorders.
•Positioning Canadian researchers, clinicians and policy-makers at the forefront of epigenetics science and its translation into health-care deliverables by playing a leadership role in IHEC and other international epigenetics initiatives.